check out cafeb2bsales.com - anonymous message boards for b2b reps


» Sponsored ads

» Sponsored ads

» Sponsored ads


Go Back   Cafepharma Message Boards > General Discussion > In the Pipe
Register Members List Calendar Search Today's Posts Mark Forums Read

Reply

 
Bookmark and Share Thread Tools Rate Thread Display Modes
  #1  
Old 02-15-2008, 02:30 AM
james smith james smith is offline
cafepharmhand
 
Join Date: Feb 2008
Posts: 47
Default Jan2008 Drug Protein Targets

indoleamine-pyrrole 2,3 dioxygenase
Indoleamine-pyrrole 2,3 dioxygenase (IDO) catalyzes the conversion of tryptophan to N-formylkynurenine, the first and rate-limiting step of tryptophan catabolism through the kynurenine pathway. Over expressed in tumour cells, IDO enables cancer cells to escape immune response, as depleted tryptophan levels sensitize activated T cells to apoptosis. Reduced tryptophan levels also halt microbe growth.

NewLink Genetics is developing NLG-001, a small molecule IDO inhibitor for the treatment of cancer.
IDO belongs to the Enzyme > Oxygenase Target Family Group and its EC number is 1.13.11.52. Its Entrez Gene ID is 3620.
peptidylprolyl isomerase B (cyclophilin B)
Sometimes referred to as CYPB or PPIB, this enzyme is predominantly located in the endoplasmic reticulum. Interactions with HIV-1 gp120 and Pr55gag as well as stimulation of the RNA binding activity of the Hepatitis C RNA polymerase NS5B have been reported.

Scynexis is developing SCY-635, a CYPB inhibitor for the treatment of HCV and HIV infection.
CYPB belongs to the Enzyme > Isomerase Target Family Group and its EC number is 5.2.1.8. Its Entrez Gene ID is 5479.

for more info, visit:
http://www.pharmaprojects.com/new_dr...tm#Indoleamine
Reply With Quote
Reply




Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may post new threads
You may post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is Off
HTML code is Off
Forum Jump


All times are GMT -5. The time now is 07:59 AM.


Powered by vBulletin® Version 3.6.11
Copyright ©2000 - 2013, Jelsoft Enterprises Ltd.